Search results
Is Eli Lilly and Company the Largest Publicly Traded Healthcare Company?
Insider Monkey via Yahoo Finance· 2 days agoIn this article, we will be taking a look at is Eli Lilly and Company the largest publicly traded...
Maintenance Tx With Guselkumab for UC Meets All Endpoints
Medscape· 3 days agoGuselkumab (Tremfya, Janssen/Johnson & Johnson) was superior to placebo for maintenance therapy in...
How biologics can help with symptoms of Crohn's
Medical News Today· 7 days agoBiologic therapies for Crohn’s disease (CD) do more than reduce the common symptoms of diarrhea, abdominal cramping, and pain. CD and ulcerative colitis...
WHO updates bacterial priority pathogens list
Center for Infectious Disease Research and Policy· 7 days agoThe list aims to provide guidance for prioritizing research and development (R&D) and investments in antimicrobial resistance (AMR) and has been used by...
Could the internet be ... good for you? Here's what to know about this week's health headlines
Yahoo Life Style via AOL· 6 days ago...this increase will be due to public health measures that reduce deaths from various communicable...
Bayer: The pharmaceutical company behind Leverkusen's success - and its difficult past
New York Times· 3 days agoUnder head coach Xabi Alonso, Bayer Leverkusen have won the Bundesliga and are on the cusp of...
Molecular Identification of Fonsecaea monophora, Novel Agent of Fungal Brain Abscess
Centers for Disease Control and Prevention· 18 hours agoA 3-year-old boy was admitted to the All India Institute of Medical Sciences, New Delhi, India, with headache for 3 weeks and 2 episodes of seizures. Fundoscopic examination revealed bilateral ...
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
NBC 17 Raleigh· 4 days agoCelltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) in adult patients with moderately to severely ...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 3 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 1 day agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...